{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:18:56Z","timestamp":1786979936859,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008678","name":"Universit\u00e4t Leipzig","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008678","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The prognosis of chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) treatment is based on the quantification of BCR::ABL1 fusion gene transcript copy number, harmonized by an international scale (IS) based on TaqMan-based real-time quantitative PCR (qRT-PCR). In Ethiopia, as in most low- and middle-income countries (LMICs), access to standard diagnostic, follow-up, and prognostic tools is very limited, and it has been challenging to strictly follow international guidelines. This seriously compromises clinical outcome, despite the availability of TKIs through the Glivec International Patient Assistance Program (GIPAP). Multiplex PCR (mpx-PCR), conventionally regarded as a \u201cscreening tool,\u201d offers a potential solution to this problem. A total of 219 samples from confirmed CML patients were assayed. In reference to qRT-PCR, the AUC of ROC curve for mpx-PCR was 0.983 (95% CI: 0.957 to 0.997). At the optimum cut-off value, equivalent to BCR::ABL1 (IS) transcript copy number of 0.6%, the specificity and sensitivity were 93% and 95%, respectively, with 94% accuracy. Albeit the sensitivity and accuracy of mpx-PCR decrease below the optimum cutoff of 0.6% (IS), the specificity at 0.1% (IS) was 100%, making it an attractive means to rule-out relapse and drug non-adherence at later stages of treatment, which is particularly an issue in a\u00a0low income setting. We conclude that the relative simplicity and low cost of mpx-PCR and prognostic relevant cutoff values (0.1\u20130.6% IS) should allow its use in peripheral clinics and thus maximize the positive impact of TKIs made available through GIPAP in most LMICs.<\/jats:p>","DOI":"10.1007\/s00277-023-05254-x","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:01:21Z","timestamp":1684713681000},"page":"1723-1729","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Estimating prognostic relevant cutoff values for a multiplex PCR detecting BCR::ABL1 in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy in resource-limited settings"],"prefix":"10.1007","volume":"102","author":[{"given":"Saifu","family":"Hailu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1028-2470","authenticated-orcid":false,"given":"Samuel","family":"Kinde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aster","family":"Tsegaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsehayneh","family":"Kelemu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Seifu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawit","family":"Alemayehu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azeb","family":"Tarekegn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gutema","family":"Jabessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desalegn","family":"Abeje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markos","family":"Abebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaziz","family":"Sherif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fisihatsion","family":"Tadesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawleigh","family":"Howe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amha","family":"Gebremedhin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,22]]},"reference":[{"issue":"3-4","key":"5254_CR1","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3109\/10428199209067600","volume":"21","author":"MC L\u00e9glise","year":"1996","unstructured":"L\u00e9glise MC, Pluchon-Rivi\u00e8re E, Le Calvez G et al (1996) Molecular diagnosis and follow up in myeloproliferative syndromes and acute leukemias: correlation between expression of fusion transcripts and disease progression in chronic myeloid leukemia. Leuk Lymphoma 21(3-4):187\u2013199. https:\/\/doi.org\/10.3109\/10428199209067600","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"5254_CR2","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","volume":"96","author":"MW Deininger","year":"2000","unstructured":"Deininger MW, Goldman JM, Melo JV (2000) The molecular biology of chronic myeloid leukemia. Blood 96(10):3343\u20133356","journal-title":"Blood"},{"issue":"3","key":"5254_CR3","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1056\/NEJM199907153410306","volume":"341","author":"S Faderl","year":"1999","unstructured":"Faderl S, Talpaz M, Estrov Z et al (1999) The biology of chronic myeloid leukemia. N Engl J Med 341(3):164\u2013172. https:\/\/doi.org\/10.1056\/NEJM199907153410306","journal-title":"N Engl J Med"},{"issue":"24","key":"5254_CR4","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bj\u00f6rkholm M, Dickman PW et al (2016) Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol 34(24):2851\u20132857. https:\/\/doi.org\/10.1200\/JCO.2015.66.2866","journal-title":"J Clin Oncol"},{"issue":"11","key":"5254_CR5","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"F-X Mahon","year":"2010","unstructured":"Mahon F-X, R\u00e9a D, Guilhot J et al (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11(11):1029\u20131035. https:\/\/doi.org\/10.1016\/S1470-2045(10)70233-3","journal-title":"Lancet Oncol"},{"key":"5254_CR6","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1146\/annurev-pathol-042320-034052","volume":"17","author":"JP Radich","year":"2022","unstructured":"Radich JP, Briercheck E, Chiu DT et al (2022) Precision medicine in low- and middle-income countries. Annu Rev Pathol 17:387\u2013402. https:\/\/doi.org\/10.1146\/annurev-pathol-042320-034052","journal-title":"Annu Rev Pathol"},{"key":"5254_CR7","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1200\/GO.21.00058","volume":"7","author":"F Tadesse","year":"2021","unstructured":"Tadesse F, Asres G, Abubeker A et al (2021) Spectrum of BCR-ABL mutations and treatment outcomes in ethiopian imatinib-resistant patients with chronic myeloid leukemia. JCO global oncology 7:1187\u20131193. https:\/\/doi.org\/10.1200\/GO.21.00058","journal-title":"JCO global oncology"},{"issue":"4","key":"5254_CR8","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT et al (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34(4):966\u2013984. https:\/\/doi.org\/10.1038\/s41375-020-0776-2","journal-title":"Leukemia"},{"issue":"10","key":"5254_CR9","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.6004\/jnccn.2020.0047","volume":"18","author":"MW Deininger","year":"2020","unstructured":"Deininger MW, Shah NP, Altman JK et al (2020) Chronic myeloid leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Nat Compr Cancer Netw 18(10):1385\u20131415. https:\/\/doi.org\/10.6004\/jnccn.2020.0047","journal-title":"J Nat Compr Cancer Netw"},{"issue":"10","key":"5254_CR10","doi-asserted-by":"publisher","first-page":"e0259076","DOI":"10.1371\/journal.pone.0259076","volume":"16","author":"VK Maheshwari","year":"2021","unstructured":"Maheshwari VK, Slader C, Dani N et al (2021) Enabling access to molecular monitoring for chronic myeloid leukemia patients is cost effective in China. PLoS One 16(10):e0259076. https:\/\/doi.org\/10.1371\/journal.pone.0259076","journal-title":"PLoS One"},{"issue":"4","key":"5254_CR11","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41591-022-01738-x","volume":"28","author":"CS Pramesh","year":"2022","unstructured":"Pramesh CS, Badwe RA, Bhoo-Pathy N et al (2022) Priorities for cancer research in low- and middle-income countries: a global perspective. Nat Med 28(4):649\u2013657. https:\/\/doi.org\/10.1038\/s41591-022-01738-x","journal-title":"Nat Med"},{"issue":"1","key":"5254_CR12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1200\/JGO.2015.000570","volume":"1","author":"P Garcia-Gonzalez","year":"2015","unstructured":"Garcia-Gonzalez P, Boultbee P, Epstein D (2015) Novel humanitarian aid program: the Glivec International Patient Assistance Program-lessons learned from providing access to breakthrough targeted oncology treatment in low- and middle-income countries. J Glob Oncol 1(1):37\u201345. https:\/\/doi.org\/10.1200\/JGO.2015.000570","journal-title":"J Glob Oncol"},{"issue":"2","key":"5254_CR13","doi-asserted-by":"publisher","first-page":"220","DOI":"10.2353\/jmoldx.2007.060112","volume":"9","author":"Z Jobbagy","year":"2007","unstructured":"Jobbagy Z, van Atta R, Murphy KM et al (2007) Evaluation of the Cepheid GeneXpert BCR-ABL assay. J Mol Diagnos 9(2):220\u2013227. https:\/\/doi.org\/10.2353\/jmoldx.2007.060112","journal-title":"J Mol Diagnos"},{"issue":"1","key":"5254_CR14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12962-021-00271-x","volume":"19","author":"S Rowley","year":"2021","unstructured":"Rowley S, Garcia-Gonzalez P, Radich JP et al (2021) Analysis of the gap in PCR monitoring availability for patients with chronic myeloid leukemia in 60 low- and middle-income countries. Cost Effect Resour Alloc 19(1):18. https:\/\/doi.org\/10.1186\/s12962-021-00271-x","journal-title":"Cost Effect Resour Alloc"},{"key":"5254_CR15","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1590\/S1415-47572007000400003","volume":"30","author":"D Sastre","year":"2007","unstructured":"Sastre D, Argara\u00f1a CE, Heller V et al (2007) An analysis of multiplex-PCR in the detection of BCR-ABL transcripts in hematological disorders. Gen Mol Biol 30:520\u2013523. https:\/\/doi.org\/10.1590\/S1415-47572007000400003","journal-title":"Gen Mol Biol"},{"issue":"4","key":"5254_CR16","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.leukres.2007.08.017","volume":"32","author":"T Burmeister","year":"2008","unstructured":"Burmeister T, Reinhardt R (2008) A multiplex PCR for improved detection of typical and atypical BCR-ABL fusion transcripts. Leuk Res 32(4):579\u2013585. https:\/\/doi.org\/10.1016\/j.leukres.2007.08.017","journal-title":"Leuk Res"},{"issue":"1","key":"5254_CR17","first-page":"186","volume":"8","author":"NC Cross","year":"1994","unstructured":"Cross NC, Melo JV, Feng L et al (1994) An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia 8(1):186\u2013189","journal-title":"Leukemia"},{"issue":"12","key":"5254_CR18","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","volume":"17","author":"J Gabert","year":"2003","unstructured":"Gabert J, Beillard E, van der Velden VHJ et al (2003) Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 17(12):2318\u20132357. https:\/\/doi.org\/10.1038\/sj.leu.2403135","journal-title":"Leukemia"},{"issue":"1","key":"5254_CR19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jmoldx.2019.08.007","volume":"22","author":"G-N Franke","year":"2020","unstructured":"Franke G-N, Maier J, Wildenberger K et al (2020) Comparison of real-time quantitative PCR and digital droplet PCR for BCR-ABL1 monitoring in patients with chronic myeloid leukemia. J Mol Diagn 22(1):81\u201389. https:\/\/doi.org\/10.1016\/j.jmoldx.2019.08.007","journal-title":"J Mol Diagn"},{"issue":"2","key":"5254_CR20","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/leu.2014.217","volume":"29","author":"H White","year":"2015","unstructured":"White H, Deprez L, Corbisier P et al (2015) A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR. Leukemia 29(2):369\u2013376. https:\/\/doi.org\/10.1038\/leu.2014.217","journal-title":"Leukemia"},{"issue":"21","key":"5254_CR21","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1182\/blood.V116.21.893.893","volume":"116","author":"MC M\u00fcller","year":"2010","unstructured":"M\u00fcller MC, Munjal U, Erben P et al (2010) Stability of conversion factors for BCR-ABL monitoring -\u2013 implications for the frequency of validation rounds. Blood 116(21):893. https:\/\/doi.org\/10.1182\/blood.V116.21.893.893","journal-title":"Blood"},{"issue":"6","key":"5254_CR22","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.jmoldx.2016.06.008","volume":"18","author":"B Biswas","year":"2016","unstructured":"Biswas B (2016) Clinical performance evaluation of molecular diagnostic tests. J Mol Diagn 18(6):803\u2013812. https:\/\/doi.org\/10.1016\/j.jmoldx.2016.06.008","journal-title":"J Mol Diagn"},{"issue":"10","key":"5254_CR23","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F et al (2017) Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med 376(10):917\u2013927. https:\/\/doi.org\/10.1056\/NEJMoa1609324","journal-title":"N Engl J Med"},{"key":"5254_CR24","doi-asserted-by":"publisher","first-page":"100257","DOI":"10.1016\/j.eclinm.2020.100257","volume":"19","author":"CA Umeh","year":"2020","unstructured":"Umeh CA, Garcia-Gonzalez P, Tremblay D et al (2020) The survival of patients enrolled in a global direct-to-patient cancer medicine donation program: the Glivec International Patient Assistance Program (GIPAP). EClinicalMedicine 19:100257. https:\/\/doi.org\/10.1016\/j.eclinm.2020.100257","journal-title":"EClinicalMedicine"},{"issue":"1","key":"5254_CR25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40164-020-00185-z","volume":"9","author":"L Ning","year":"2020","unstructured":"Ning L, Hu C, Lu P et al (2020) Trends in disease burden of chronic myeloid leukemia at the global, regional, and national levels: a population-based epidemiologic study. Exp Hematol Oncol 9(1):29. https:\/\/doi.org\/10.1186\/s40164-020-00185-z","journal-title":"Exp Hematol Oncol"},{"key":"5254_CR26","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1200\/GO.21.00194","volume":"7","author":"Y Hu","year":"2021","unstructured":"Hu Y, Li Q, Hou M et al (2021) Magnitude and temporal trend of the chronic myeloid leukemia: on the basis of the Global Burden of Disease Study 2019. JCO global oncology 7:1429\u20131441. https:\/\/doi.org\/10.1200\/GO.21.00194","journal-title":"JCO global oncology"},{"issue":"14","key":"5254_CR27","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1182\/blood-2012-11-466037","volume":"121","author":"P Neelakantan","year":"2013","unstructured":"Neelakantan P, Gerrard G, Lucas C et al (2013) Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. Blood 121(14):2739\u20132742. https:\/\/doi.org\/10.1182\/blood-2012-11-466037","journal-title":"Blood"},{"key":"5254_CR28","doi-asserted-by":"publisher","unstructured":"Stella S, Zammit V, Vitale SR et al (2019) Clinical implications of discordant early molecular responses in CML patients treated with imatinib. Int J Mol Sci 20(9). https:\/\/doi.org\/10.3390\/ijms20092226","DOI":"10.3390\/ijms20092226"},{"issue":"3","key":"5254_CR29","doi-asserted-by":"publisher","first-page":"e0213557","DOI":"10.1371\/journal.pone.0213557","volume":"14","author":"A Mulu Fentie","year":"2019","unstructured":"Mulu Fentie A, Tadesse F, Engidawork E et al (2019) Prevalence and determinants of non-adherence to Imatinib in the first 3-months treatment among newly diagnosed Ethiopian's with chronic myeloid leukemia. PLoS One 14(3):e0213557. https:\/\/doi.org\/10.1371\/journal.pone.0213557","journal-title":"PLoS One"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05254-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05254-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05254-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T02:07:08Z","timestamp":1686535628000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05254-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,22]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["5254"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05254-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,22]]},"assertion":[{"value":"29 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}